Clinical trials
Advanced Solid Tumor clinical trials
Below are recruiting advanced solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,391 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06616766RecruitingPhase 1/Phase 2
Study of YH42946 for advanced cancer with HER2 or EGFR changes
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
Fairfax, VirginiaAges 18 years+ - NCT04686682RecruitingPhase 1/Phase 2
Study drug for adults with advanced cancers or AML
This early study (Phase 1/2) tests a new medicine (JAB-8263) in adults with advanced solid tumors or recurrent/refractory AML. It aims to find a safe dose and see whether it can shrink tumors or control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05956587RecruitingPhase 2
Testing two study drugs for advanced lung cancer and other tumors
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05969041RecruitingPhase 1
Early-phase drug trial for advanced epithelial cancers
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
Darlinghurst, New South WalesAges 18 years+ - NCT04511039RecruitingPhase 1
New targeted pill combo for advanced colon or stomach cancers
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Buffalo, New YorkAges 18 years+ - NCT05533983Recruiting
Stool transplant plus nivolumab for advanced solid cancers
This study tests whether transferring stool microbiome (“FMT,” stool transplant) along with nivolumab can improve outcomes in people with advanced solid cancers that kept worsening even after anti–PD-1/PD-L1 treatment. It also looks at stool and blood changes to understand why the treatment might work.
SeoulAges 19 years+ - NCT07426055RecruitingPhase 2/Phase 3
Prostate cancer radiation boost comparison study
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT05301101Recruiting
Re-irradiation planning for tumors near previously treated organs
This study tests a more personalized way to plan “re-irradiation,” meaning giving radiation again in an area that was already treated before. It aims to better calculate organ risk to reduce harmful side effects while treating cancer.
Milwaukee, WisconsinAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT07137416RecruitingPhase 1
Testing a new combination of cancer drugs for HER2-positive tumors and breast cancer
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
Boston, MassachusettsAges 18 years+ - NCT07067385RecruitingPhase 1
Personalized mRNA vaccine for advanced GI cancers
This trial tests a personalized mRNA vaccine designed to teach your immune system to attack your specific tumor. It is for people with advanced gastrointestinal cancers who have exhausted other options.
Shanghai, SHAges 18 years+ - NCT07628634RecruitingEarly Phase 1
Testing a Low-Methionine Diet in Solid Tumor Patients
This early-stage study explores whether eating a diet low in methionine (a natural amino acid found in protein) might help people with advanced solid tumors. Researchers will track how this dietary change affects blood levels and may improve treatment outcomes alongside standard cancer care.
Orange, CaliforniaAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Gilbert, ArizonaAges 18 years+ - NCT07276373RecruitingPhase 1/Phase 2
Nenocorilant with nivolumab for advanced solid tumors
This trial tests a new drug called nenocorilant combined with nivolumab (an immunotherapy) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT07247110RecruitingPhase 1
Study of MK-4716 for people with certain solid tumors
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
New Brunswick, New JerseyAges 18 years+ - NCT06227377RecruitingPhase 1
A new drug for cancers with KRAS G12D mutation
This trial tests a new drug called QTX3034 in people whose cancer has a specific genetic change called KRAS G12D. The drug aims to block the mutated protein that helps cancer grow, and may work even if other treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT06327997RecruitingEarly Phase 1
Fast CAR-T cells for advanced solid tumors
This trial tests a new type of 'fast CAR-T' cell therapy for people with advanced solid tumors that have not been helped by standard treatments. CAR-T cells are a kind of immune cell that is reprogrammed to attack cancer cells that carry certain markers called mesothelin, MUC1, and PD-L1.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04762862Enrolling by invitation
Testing gene-guided cancer treatment changes in advanced tumors
This trial studies whether measuring changes in your tumor’s genes (from pangenomic quantitative testing) can help guide cancer treatment when standard cures aren’t available. It may help doctors choose therapies based on what your tumor shows.
NiceAges Any age - NCT07231120RecruitingPhase 1
Testing SXRN injection for cancer-related weight loss
This trial tests a new injection called SXRN for people with advanced cancer who have lost weight and appetite (cancer cachexia). The goal is to see if it is safe and might help improve weight and appetite.
Beijing, Beijing MunicipalityAges 18–75 - NCT05390827Recruiting
Remote digital health data collection for cancer patients
This study collects health data from digital devices (like Apple iPhone or Android) to help researchers understand how physical activity and other measures change during cancer treatment. It may be a way for you to contribute to research from home.
New York, New YorkAges 18 years+ - NCT06436157Recruiting
Genetic testing support through a nurse-led program
This study tests whether a special program led by oncology nurses can help more people with solid tumor cancers get genetic testing. If you are starting a new treatment and have not had genetic testing before, this program may help you learn about your cancer risks and treatment options.
Chico, CaliforniaAges 18 years+ - NCT07192432RecruitingPhase 1/Phase 2
Gene therapy for HER2-positive cancer
This trial tests a new gene therapy for people with HER2-positive cancer. It is for two groups: those with advanced cancer that has worsened after treatment, and those with early-stage cancer at high risk of coming back. The goal is to see if the therapy can safely help shrink tumors or prevent return.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor?
- Yes. Clin2 currently lists 1,391 recruiting advanced solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.